Trial Profile
A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Camidanlumab tesirine (Primary)
- Indications Adult T-cell leukaemia-lymphoma; B-cell lymphoma; Burkitt's lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; First in man
- Sponsors ADC Therapeutics
- 01 Jan 2023 Results assessing the camidanlumab tesirine (Cami) exposure-response (E-R) relationships, using an integrated population pharmacokinetic model, for patients with classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma, published in the Cancer Chemotherapy and Pharmacology.
- 01 Jan 2023 Based on this trial, population pharmacokinetic analysis was carried out to characterize camidanlumab tesirine pharmacokinetics, published in the Cancer Chemotherapy and Pharmacology.
- 26 May 2021 Results published in the ADC Therapeutics Media Release.